RXRX Company Profile and Key Details
NASDAQ : RXRX
Recursion Pharmaceuticals
$3.65
0.09+2.53%
Open: 1:53 PM73.23
BESG ScoreESG Rating
Price Chart
Stock Price Today
Recursion Pharmaceuticals, Inc. (RXRX) stock surged +2.53%, trading at $3.65 on NASDAQ, up from the previous close of $3.56. The stock opened at $3.61, fluctuating between $3.61 and $3.71 in the recent session.
Stock Snapshot
3.56
Prev. Close
1.63B
Market Cap
3.61
Day Low
-2.53
P/E Ratio
-1.44
EPS (TTM)
-1.29
Cash Flow per Share
3.61
Open
447.19M
Number of Shares
3.7111
Day High
77.49%
Free Float in %
1.99
Book Value
6M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 21, 2026 | 3.70 | 3.74 | 3.55 | 3.56 | 11.8M |
| Apr 20, 2026 | 3.71 | 3.80 | 3.66 | 3.69 | 9.76M |
| Apr 17, 2026 | 3.74 | 3.88 | 3.71 | 3.78 | 14.01M |
| Apr 16, 2026 | 3.85 | 3.90 | 3.53 | 3.60 | 16.21M |
| Apr 14, 2026 | 3.49 | 3.55 | 3.47 | 3.54 | 8.98M |
| Apr 13, 2026 | 3.25 | 3.43 | 3.23 | 3.42 | 8.69M |
| Apr 10, 2026 | 3.32 | 3.38 | 3.24 | 3.28 | 8.57M |
| Apr 09, 2026 | 3.33 | 3.44 | 3.27 | 3.31 | 8.69M |
| Apr 08, 2026 | 3.39 | 3.46 | 3.29 | 3.39 | 15.57M |
| Apr 07, 2026 | 3.12 | 3.20 | 3.04 | 3.19 | 10.05M |
| Apr 06, 2026 | 3.12 | 3.22 | 3.11 | 3.15 | 8.37M |
| Apr 02, 2026 | 2.94 | 3.13 | 2.93 | 3.11 | 9.24M |
| Apr 01, 2026 | 3.13 | 3.21 | 3.04 | 3.06 | 10.78M |
| Mar 31, 2026 | 2.90 | 3.07 | 2.90 | 3.07 | 13.8M |
| Mar 30, 2026 | 2.93 | 2.94 | 2.80 | 2.84 | 16.64M |
| Mar 27, 2026 | 3.09 | 3.12 | 2.91 | 2.94 | 18.97M |
| Mar 25, 2026 | 3.22 | 3.29 | 3.11 | 3.17 | 13.44M |
| Mar 24, 2026 | 3.20 | 3.21 | 3.08 | 3.17 | 12.94M |
| Mar 23, 2026 | 3.25 | 3.33 | 3.22 | 3.23 | 11.13M |
| Mar 20, 2026 | 3.35 | 3.42 | 3.21 | 3.25 | 25.96M |
Contact Details
About Company
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Company Information
| Employees | 800 |
| Beta | 1.01 |
| Sales or Revenue | $44.58M |
| 5Y Sales Change% | 19.78% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
-29.07-3.48%
argenx SE$805.38REGN-2.05-0.27%
Regeneron Pharmaceuticals, Inc.$747.36UTHR0.020.00%
United Therapeutics Corporation$573.46MDGL0.58+0.11%
Madrigal Pharmaceuticals, Inc.$527.69VRTX-2.59-0.59%
Vertex Pharmaceuticals Incorporated$436.59PRAX-1.73-0.51%
Praxis Precision Medicines, Inc.$340.84KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83ALNY-2.51-0.81%
Alnylam Pharmaceuticals, Inc.$308.43KRYS-3.84-1.39%
Krystal Biotech, Inc.$272.66ASND-5.09-2.07%
Ascendis Pharma A/S$240.29Company Overview
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) closed at $3.66 USD, gaining $0.10 (2.81%) from the previous close of $3.56. The stock is currently mid-range between its 52-week high and low $2.80 and $7.18. With a market capitalization of about $1.64 billion, Recursion Pharmaceuticals, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.01). Key stats such as the average daily volume over the past year has been around 16.38 million shares, volume is running light vs its 52-week average. Headquartered in Salt Lake City, UT, Recursion Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Najat Khan, the company employs approximately 800 people and listed since April 16, 2021. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
Technical Performance
Short-term trend indicators are bullishly aligned (SMA20 -0.07%, SMA50 -10.38%, SMA200 -22.56%). The stock’s 14-day RSI is 46.4 (neutral), while the ATR of 0.3 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -56.62% below its high and over 26.51% above its low. Average 10-day trading volume of 11.57 million shares is below the 3-month average of 16.74 million, indicating normal recent market interest.
Valuation Metrics
Recursion Pharmaceuticals, Inc. trades at a P/E ratio of -2.94, slightly below the S&P 500 average, with a price-to-sales ratio of 21.56 and a price-to-book ratio of 1.67 suggesting the stock is closer to book value. The P/FCF stands at -4.25, also below market averages.
Dividend & Fair Value
Dividend and splits history remains an important factor for investors monitoring long-term returns.
Earnings & Analyst Outlook
Recursion Pharmaceuticals, Inc. generated EPS of -$1.48 over the past year. Five-year average earnings growth is -22.39%. The latest quarter delivered EPS of -$0.36. The next quarter is forecast at -$0.26. Next year's EPS is expected at -$14.17. Analyst sentiment is neutral. Analyst rating data shows there are 1 Strong Buy ratings, 3 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $11.00 to $5.00. The high target offers 208.99% upside. The low target suggests 40.45% downside. The mean target is $7.43. This offers 108.71% upside. Recursion Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -4.48%. The prior quarter beat by 17.14%. Over the last six quarters, Apple has recorded several small beats. These include 14.29% in August 08, 2024.
Shareholding & Insider Activity
Recursion Pharmaceuticals, Inc. has 429.71 million shares outstanding. The public float is 416.22 million shares, elevated short interest at 30.22% of float. This equals 122.22 million shares. The short ratio is 4.63 days. Institutional investors hold 66.48% of the float. Insiders own 2.85%. Borgeson Blake holds 6.23 million shares, Khan Najat has 2.26 million shares and Secora Michael has 1.50 million shares. Over the past six months, insider transactions show net selling. They sold 1.56 million shares across 21 transactions.
Frequently Asked Questions
What is the current Recursion Pharmaceuticals, Inc. (RXRX) stock price?
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) stock price is $3.65 in the last trading session. During the trading session, RXRX stock reached the peak price of $3.71 while $3.61 was the lowest point it dropped to. The percentage change in RXRX stock occurred in the recent session was 2.53% while the dollar amount for the price change in RXRX stock was $0.09.
RXRX's industry and sector of operation?
The NASDAQ listed RXRX is part of Biotechnology industry that operates in the broader Healthcare sector. Recursion Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of RXRX?
Mr. Ryan Kelly
Managing Director
Dr. Michael Secora Ph.D.
Chief Financial Officer
Ms. Tina Marriott Larson
Chief Operating Officer & Pres
Ms. Louisa Daniels J.D., M.B.A.
Chief Legal Officer & Gen. Counsel
Kevin Leggat
Vice President of Fin. & Accounting
Dr. Blake C. Borgeson Ph.D.
Co-Founder & Director
Dr. Christopher C. Gibson Ph.D.
Co-Founder, Chief Executive Officer & Director
Mr. Benjamin Mabey M.S.
Chief Technology Officer
Dr. Shafique Virani M.D.
Chief Corporation Devel. Officer
Mr. Jared Allenbach
Senior Director of Investor Relations
Ms. Heather Kirkby M.B.A.
Chief People Officer
Managing Director
Dr. Michael Secora Ph.D.
Chief Financial Officer
Ms. Tina Marriott Larson
Chief Operating Officer & Pres
Ms. Louisa Daniels J.D., M.B.A.
Chief Legal Officer & Gen. Counsel
Kevin Leggat
Vice President of Fin. & Accounting
Dr. Blake C. Borgeson Ph.D.
Co-Founder & Director
Dr. Christopher C. Gibson Ph.D.
Co-Founder, Chief Executive Officer & Director
Mr. Benjamin Mabey M.S.
Chief Technology Officer
Dr. Shafique Virani M.D.
Chief Corporation Devel. Officer
Mr. Jared Allenbach
Senior Director of Investor Relations
Ms. Heather Kirkby M.B.A.
Chief People Officer
How RXRX did perform over past 52-week?
RXRX's closing price is 27.14% higher than its 52-week low of $2.80 where as its distance from 52-week high of $7.18 is -50.42%.
How many employees does RXRX have?
Number of RXRX employees currently stands at 800.
Link for RXRX official website?
Official Website of RXRX is: https://www.recursion.com
How do I contact RXRX?
RXRX could be contacted at phone 385 269 0203 and can also be accessed through its website. RXRX operates from 41 South Rio Grande Street, Salt Lake City, UT 84101, United States.
How many shares of RXRX are traded daily?
RXRX stock volume for the day was 6M shares. The average number of RXRX shares traded daily for last 3 months was 16.38M.
What is the market cap of RXRX currently?
The market value of RXRX currently stands at $1.63B with its latest stock price at $3.65 and 447.19M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep